Shares of Protalix (PLX) +4.4% premarket after a report says the firm will file a request with...

|About: Protalix BioTherapeutics,... (PLX)|By:, SA News Editor

Shares of Protalix (PLX) +4.4% premarket after a report says the firm will file a request with the FDA within days for approval of the firm's Gaucher's disease treatment Uplyso.